22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- 2,309 regulations filed with China's top legislature for review in 2025
- Chinese researchers pinpoint seed genes for enhancing food security
- Public interest litigation plays prominent role in China's governance
- 15 arrested in 1b yen robbery in Hong Kong
- Chinese lawmakers conduct third deliberation of draft national development planning law
- Multiple cities probe illegal activities in 'private cinemas'
